Current Cancer Therapy Reviews最新文献

{"title":"Anti-cancer Potential of Phytoflavonoidal Drugs against Gynecological\u0000Cancer","authors":"Kavita Sangwan, Parveen Kumar Goyal","doi":"10.2174/0115733947289878240126111236","DOIUrl":"https://doi.org/10.2174/0115733947289878240126111236","url":null,"abstract":"\u0000\u0000Flavonoids, one of the major bioactive constituents of herbal drugs, have\u0000been scientifically reported to possess diverse therapeutic potentials such as anticancer, immunomodulatory, neuroprotective, cardioprotective, antioxidant, etc. This manuscript enlightens the anticancer\u0000potential of traditional herbal flavonoids in gynecological cancer i.e., is one of the major life-threats\u0000in women.\u0000\u0000\u0000\u0000This manuscript is aimed at an insightful compilation of scientific substantiations of herbal\u0000flavonoids in gynecological cancer along with targeted drug delivery systems for the same.\u0000\u0000\u0000\u0000The contents and data represented in the article have been reviewed using\u0000institutional libraries and online database resources (available in the public domain) such as PubMed,\u0000Science-Direct, Web of Science, American Association of Pharmaceutical Scientists, Google Scholar,\u0000Hinari, SciFinder, Research Gate, etc.\u0000\u0000\u0000\u0000Flavonoids are natural compounds and have potential against cervical, ovarian, and endometrial cancer. In-vitro and in-vivo experiments have demonstrated the significant potential of flavonoids in gynecological cancer, especially cervical, ovarian, and endometrial cancer. It was reported\u0000from in-vitro experimentations that targeted drug delivery system improves the anticancer effect of\u0000flavonoids.\u0000\u0000\u0000\u0000Phytoflavonoids have the potential to prevent gynecological cancer by induction of\u0000apoptosis cell cycle arrest and reactive oxygen species generation. Further studies on the drug delivery system of flavonoids are warranted.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"90 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139794793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Borderline Brenner Tumor of the Ovary in a Postmenopausal Woman: A\u0000Rare Case with Concomitant Endometrial Hyperplasia and Endocervical\u0000Polyp","authors":"Naina Kumar, I. Pradeep, Annapurna Srirambhatla, K. Poojitha, M. Mangla","doi":"10.2174/0115733947256172231128064128","DOIUrl":"https://doi.org/10.2174/0115733947256172231128064128","url":null,"abstract":"\u0000\u0000Bordeline Brenner tumors of the ovary are rare tumors accounting for 2% of\u0000all ovarian tumors and are characterized by the presence of papillary structures covered with transitional\u0000epithelium without or minimal stromal invasion.\u0000\u0000\u0000\u0000In the present case report a 60-year-old postmenopausal woman presented with\u0000complaints of lower abdominal pain and a right ovarian mass of 4x5cm, which was diagnosed on histopathological\u0000examination as borderline Brenner tumor of the ovary. There were coexisting nonatypical\u0000endometrial hyperplasia and endocervical polyps of 1.2x0.9x0.6cm, indicating endometrial\u0000hyperstimulation as a result of estrogen secreted by the tumor. The patient was managed successfully\u0000with staging laparotomy and was diagnosed with stage I borderline Brenner tumor with non-atypical\u0000endometrial hyperplasia and benign endocervical polyp.\u0000\u0000\u0000\u0000Borderline Brenner tumors are rare tumors of ovaries with uncertain malignant potential.\u0000They have no precise predictive markers but are known to produce estrogen. Surgery remains the\u0000mainstay of treatment for these tumors.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"4 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139821541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Borderline Brenner Tumor of the Ovary in a Postmenopausal Woman: A\u0000Rare Case with Concomitant Endometrial Hyperplasia and Endocervical\u0000Polyp","authors":"Naina Kumar, I. Pradeep, Annapurna Srirambhatla, K. Poojitha, M. Mangla","doi":"10.2174/0115733947256172231128064128","DOIUrl":"https://doi.org/10.2174/0115733947256172231128064128","url":null,"abstract":"\u0000\u0000Bordeline Brenner tumors of the ovary are rare tumors accounting for 2% of\u0000all ovarian tumors and are characterized by the presence of papillary structures covered with transitional\u0000epithelium without or minimal stromal invasion.\u0000\u0000\u0000\u0000In the present case report a 60-year-old postmenopausal woman presented with\u0000complaints of lower abdominal pain and a right ovarian mass of 4x5cm, which was diagnosed on histopathological\u0000examination as borderline Brenner tumor of the ovary. There were coexisting nonatypical\u0000endometrial hyperplasia and endocervical polyps of 1.2x0.9x0.6cm, indicating endometrial\u0000hyperstimulation as a result of estrogen secreted by the tumor. The patient was managed successfully\u0000with staging laparotomy and was diagnosed with stage I borderline Brenner tumor with non-atypical\u0000endometrial hyperplasia and benign endocervical polyp.\u0000\u0000\u0000\u0000Borderline Brenner tumors are rare tumors of ovaries with uncertain malignant potential.\u0000They have no precise predictive markers but are known to produce estrogen. Surgery remains the\u0000mainstay of treatment for these tumors.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"5 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139881655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abdomen Malignant Myxoid Leiomyosarcoma with PDGFRA and TP53\u0000Missense Mutation: A Case Report","authors":"Yao-xuan Li, Jian-ping Yu, Yan-qing Gong, Hai-fu Huang, Xian-lin Wu","doi":"10.2174/0115733947276376231102103138","DOIUrl":"https://doi.org/10.2174/0115733947276376231102103138","url":null,"abstract":"\u0000\u0000Malignant myxoid leiomyosarcoma (MMLS) is most commonly found in\u0000the uterus but can also occur in other areas, such as the extremities, vulva, chest wall, and abdominal\u0000cavity. This cancer is more prevalent in women and has a poor prognosis with a high rate of recurrence and a significant percentage of metastasis.\u0000\u0000\u0000\u0000Herein, we report the case of a 64-year-old female patient who presented with\u00003-month history of left lower abdominal mass. The patient underwent abdominal malignancy resection and was subsequently diagnosed with myxoid leiomyosarcoma. The patient experienced a recurrence and metastasis with significant ascites after the initial surgery and did not respond to treatment\u0000with oral Anrotinib in combination with Tislelizumab immunotherapy. Further genetic testing using\u0000next-generation sequencing (NGS) identified missense mutations in the PDGFRA and TP53 genes in\u0000the patient's plasma, but no mutations in the KIT gene were detected. Immunohistochemical analysis\u0000of the tumor tissue also revealed a negative expression of PD-L1. As a result, we altered her targeted\u0000therapy to Avapritinib, which resulted in significant improvement in her symptoms, including abdominal distension and pain, a decrease in ascites, and the KPS score increased from 60 points before\u0000treatment to 90 points after treatment SD (stable disease) was achieved for three months after treatment.\u0000\u0000\u0000\u0000In this case report, we present the instance of a patient with malignant myxoid leiomyosarcoma with a missense mutation in both the PDGFRA and TP53 genes. We found that targeted\u0000therapy with Avapritinib was effective in achieving a positive outcome in this patient. Our findings\u0000suggest that genetic detection is possible to better understand the biological behavior, genetic characteristics, and patient's response and tolerance to certain drugs, thus selecting the best treatment plan\u0000for the patient. Avapritinib may be a promising new treatment option for leiomyosarcoma patients\u0000with similar genetic mutations.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"313 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140484548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Advancement in Nanotechnological Approaches for Increasing\u0000the Effectiveness of Herbal Drugs in the Treatment of Colorectal Cancer","authors":"Archana, Rohitas Deshmukh","doi":"10.2174/0115733947279599231208095726","DOIUrl":"https://doi.org/10.2174/0115733947279599231208095726","url":null,"abstract":"\u0000\u0000Colorectal cancer (CRC) ranks as the third most prevalent cancer type and the second leading\u0000cause of cancer-related deaths globally. The mortality rate from colon cancer has seen a significant\u0000increase, correlating with the widespread adoption of Western dietary habits and lifestyles. Medicinal\u0000plants, notably those containing functional phytochemicals like polysaccharides, exhibit antitumor\u0000and anti-apoptotic properties, offering potential for CRC prevention and treatment. Enhancing\u0000the efficacy of herbal medicines and addressing problems related to them could eventually become\u0000possible with the help of nanoscale drug delivery systems. Improved solubility and bioavailability,\u0000protection from toxicity, resistance to physical and chemical degradation, increased pharmacological\u0000activity, better distribution to tissue macrophages, and more stable are merely some of the benefits of\u0000developing nano dosage forms for herbal drugs in phyto-formulation research. The article has been\u0000drafted by gathering recent information available inScopus, ScienceDirect, Pubmed, Medline and\u0000Web of Science databases. The inclusion criterion was an English language article showing the effective\u0000use of whole plant or herbal products in CRC. Original articles and short communications on in\u0000vivo and in vitro experiments were included. Exclusion criteria included irrelevant studies, insufficient\u0000data, and mushroom or algae investigations. Case reports/case series, and letters to editors were\u0000not included but used to discover applicable primary material. This review suggests medicinal plants\u0000can produce anti-CRC chemicals. Herbs and spices with antiproliferative and angiogenesis-inhibiting\u0000properties may be useful as chemopreventive or chemotherapeutic therapies for colorectal cancer.\u0000This narrative review explores the usefulness of medicinal plants in the treatment of CRC using a\u0000novel drug delivery system. Nanotechnology is highlighted as a driving force behind the recent\u0000breakthroughs in CRC screening, diagnosis, and therapy. This review seeks to inform researchers on\u0000nanotechnology in CRC and inspire innovative nanotechnology-based therapies.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"20 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140494274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological Potential and Therapeutic Effectiveness of a Polyethylene Alkyne Class Phytochemical ‘Atractylodin’ in Medicine for the Treatment\u0000of Cancer and other Human Complications","authors":"D. Patel, K. Patel","doi":"10.2174/0115733947265189231129105327","DOIUrl":"https://doi.org/10.2174/0115733947265189231129105327","url":null,"abstract":"\u0000\u0000Atractylodes lancea Thunb. (Asteraceae) is a commonly used medicinal\u0000plant for gastric and appetite-associated complications in traditional Chinese medicine. The rhizome\u0000of Atractylodes lancea has been widely used for the treatment of human complications. Atractylodin\u0000has anti-angiogenic, anti-cancer, anti-inflammatory, anti-microbial, anti-pyretic and anti-hypertensive\u0000potential in medicine. Nano-formulations of atractylodin were also prepared in the scientific field\u0000to enhance its water solubility and efficacy in cholangiocarcinoma.\u0000\u0000\u0000\u0000Health-beneficial aspects of atractylodin in medicine have been investigated in the present\u0000work through collected scientific information on atractylodin from different literature databases. Scientific\u0000data on atractylodin has been collected from Google, Science Direct, Scopus, and PubMed.\u0000Further, detailed pharmacological activities and analytical aspects of atractylodin were discussed in\u0000this paper in order to know its biological potential in medicine. Analytical techniques of atractylodin\u0000were also discussed in the present work for separation, isolation, and identification of atractylodin.\u0000\u0000\u0000\u0000Scientific data analysis signified the biological importance of Atractylodes lancea Thunb.\u0000and its active phytochemical atractylodin in medicine. Scientific data signified the presence of atractylodin\u0000in Atractylodes lancea, Atractylodes chinensis, Atractylodes japonica, Atractylodes macrocephala,\u0000Atractylodes ovate and Atractylodis Rhizoma. Atractylodin has a significant biological\u0000effect on cholangiocarcinoma, hepatocellular carcinoma, breast cancer, lung cancer, cancer anorexiacachexia\u0000syndrome, colitis, rheumatoid arthritis, respiratory complications, GIT complications, hepatic\u0000complications, atopic dermatitis, aging process, neurodegenerative disease, calcified aortic valve\u0000disease, hypertension, pulmonary fibrosis, body temperature, olfactory neurons, podocyte hypermotility\u0000and toxicity. Further, its anti-nociceptive, anti-fibrotic, anti-angiogenic, anti-virulence, antibacterial,\u0000insecticidal, lipase inhibitory potential, immunomodulatory, and positive inotropic effects\u0000were also discussed in the present paper. Analytical techniques for the separation, isolation and identification\u0000of atractylodin in different samples were also discussed in the present work.\u0000\u0000\u0000\u0000The present work's scientific data signified the biological importance of atractylodin in\u0000medicine.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"11 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140495093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Molecular Docking and Molecular Dynamic Effects of Omeprazole on\u0000CDKs 2, 4, and 6 as a Potential CDK Inhibitor in Cancer Treatment","authors":"N. Jamali, Roohollah Mohseni, Mansoor Zareei, Javad Saffari-Chaleshtori","doi":"10.2174/0115733947274344231116113325","DOIUrl":"https://doi.org/10.2174/0115733947274344231116113325","url":null,"abstract":"\u0000\u0000Cyclin-dependent kinases (CDKs) are serine/threonine kinase proteins that\u0000regulate the cell cycle through phosphorylation and dephosphorylation. These proteins are a main\u0000target in cancer therapy. This study investigated the effect of omeprazole on CDK2, CDK4, and\u0000CDK6 through simulation studies.\u0000\u0000\u0000\u0000To investigate the interaction between omeprazole and CDK2, 4, and 6, the threedimensional structure of omeprazole was obtained from PubChem, and the structures of CDK2, 4, and 6 were acquired from RCSB servers. The proteins were then simulated for 50 nanoseconds using the GROMACS 2021 platform before the docking process. Next, Autodock v.4.2.6 software was used to bind omeprazole as a ligand to these proteins, and a molecular dynamics simulation of the resulting protein-ligand complex was conducted using GROMACS after the docking process.\u0000\u0000\u0000\u0000Omeprazole exhibited a high affinity for interacting with CDK2, 4, and 6, mainly occurring\u0000in the ATP binding site of CDK4. However, the docking of omeprazole in the CDKs induced conformational\u0000changes in their structures, which could potentially affect their function and lead to cell\u0000cycle arrest.\u0000\u0000\u0000\u0000Omeprazole, which is a proton pump inhibitor, can induce cell cycle arrest by interacting\u0000with the ATP-binding site of CDK4. Moreover, it can also induce conformational changes in\u0000CDK2, CDK4, and CDK6 through high-affinity interactions with specific amino acid residues.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"82 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139526420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alterations of the Gut Microbiome and Metabolome Following: A\u0000Opportunity for Early Detection of Colorectal Cancer","authors":"Mehdi Pezeshgi Modarres, Mohamad Amin Habibi, M. Pashaei, Yousef Mohammadpour, Kimia Jazi, S. Ahmadpour","doi":"10.2174/0115733947270529231116114913","DOIUrl":"https://doi.org/10.2174/0115733947270529231116114913","url":null,"abstract":"\u0000\u0000Colorectal cancer (CRC) is a commonly diagnosed cancer responsible for numerous deaths\u0000worldwide. In recent decades, technological advances implicated in considering the molecular pathways\u0000underlying CRC pathogenesis. Several investigations have identified various mechanisms involved\u0000in CRC and have paved the way for new therapeutics and early diagnosis. Gut microbiome\u0000play a crucial role in intestinal inflammation and can be associated with colitis colorectal cancer. In\u0000this review, we narrated the role of the microbiome population and their metabolome profile as a new\u0000screening method for early detection of CRC.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"37 7-8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140505605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decoding the Mistry of Blood Cancer cause and diagnosis of management.","authors":"Raja Sharma, Satendra Kumar, Niranjan Kaushik, Bahadur Singh","doi":"10.2174/0115733947263279231114111550","DOIUrl":"https://doi.org/10.2174/0115733947263279231114111550","url":null,"abstract":"\u0000\u0000Leukaemia, lymphoma, and myeloma are among the serious and frequently fatal conditions\u0000that impact thousands of people each year. Genetics, environmental factors, and medical problems\u0000can all affect the risk of developing blood cancer, however, the precise causes are still not entirely\u0000known. Fatigue, unexpected weight loss, and frequent infections are examples of common\u0000blood cancer symptoms. In the course of the diagnosis process, blood tests, imaging tests, and bone\u0000marrow biopsies are frequently combined. Blood cancer therapies include chemotherapy, radiation\u0000therapy, stem cell transplant, targeted therapy, and immunotherapy. Supportive care is also important\u0000for managing symptoms and improving quality of life. Ongoing research is exploring new treatments\u0000and therapies for blood cancer, as well as ways to improve supportive care and personalize treatment\u0000plans. Blood cancer patients and their families have severe emotional and psychological effects that\u0000must not be ignored. For improving outcomes and raising the general standard of living for people\u0000affected by this condition, it is essential to address these needs.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"14 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140506268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relevance of Conventional Herbal Remedies in the Prevention and Treatment\u0000of Malignant Tumors: Looking Toward the Future","authors":"Priyanka Bajpai, Phool Chandra","doi":"10.2174/0115733947266657231114075805","DOIUrl":"https://doi.org/10.2174/0115733947266657231114075805","url":null,"abstract":"\u0000\u0000The second most prevalent cause of fatalities globally is malignant tumors.\u0000The avoidance and therapy of cancer proliferation still have many prospects for betterment despite\u0000enormous advancements. Chemotherapy can occasionally have a lot of unfavorable adverse reactions.\u0000Novel agents from botanicals, especially the use of cancer therapeutic ingredients, may decrease negative\u0000consequences.\u0000\u0000\u0000\u0000There are currently several products from plants used for fighting cancer. However, numerous\u0000plant chemicals have not yet been examined in people but show extremely encouraging invitro\u0000anti-cancer properties. Further research is required to determine whether these plant chemicals\u0000are beneficial in treating human cancers.\u0000\u0000\u0000\u0000The present work has focused on the various traditional herbal remedies and the phytochemicals\u0000that exhibited promising anticancer impact. The desirable activity may be due to novel agents\u0000isolated from plant sources.\u0000\u0000\u0000\u0000The present investigations address natural ingredients for cancer treatment and chemoprevention\u0000that are now being used in clinical settings and/or are undergoing clinical studies. Potential\u0000research concentrating on naturally anticancer drugs can create an entirely novel avenue in the\u0000fight against cancer that could significantly boost the chance of survival for cancer patients.\u0000","PeriodicalId":503819,"journal":{"name":"Current Cancer Therapy Reviews","volume":"6 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140508459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}